Latest Quote @ Sat Nov 21 14:15:18 (15 min delayed)
Bid
Ask
Last
Change $
Change %
Volume
N/A
N/A
$12.44
-0.33
-2.58%
1.36M
Last Day's Data
Closing Price
High
Value Change
Percent Change
Dividend
Previous Close
$
12.44
$
12.77
$
-0.33
-2.58%
0.00
$
12.77
Opening Price
Low
Volume
Market Cap
Average Volume
P/E
$
12.74
$
12.42
1.36M
1.76B
2.69M
-7.36
Pivot Table
R2
R1
Pivot
S1
S2
12.89
12.66
12.54
12.31
12.19
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.
Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
Provide you stock picks (breakouts) and market direction to help you become
more profitable.
Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More
Stock quotes, stock research, stock scan and picks and free stock chart pattern recognition from Trending 123.com for smart stock market investing. We feature daily stock market email alerts including equities, indices, and currencies, identified through technical analysis trends patterns and waves. Sign up today!
Financial Market Data powered by Quotemedia.com. All rights reserved. Terms and conditions.
NYSE/AMEX data delayed 20 minutes. NASDAQ/other data delayed 15 minutes unless indicated.
